Batiraxcept
- Generic Name
- Batiraxcept
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2268717-61-7
- Unique Ingredient Identifier
- B6840JH4EB
- Associated Conditions
- -
- Associated Therapies
- -
CORRECTING and REPLACING PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical
PharmaEssentia USA Corporation appoints Dr. Robert Geller as Head of Medical. Dr. Geller, with extensive experience in oncology and biotech, will oversee U.S. clinical operations. PharmaEssentia aims to advance treatments for hematological diseases, focusing on ropeginterferon alfa-2b-njft (BESREMi®).
Pipeline Moves: Prospects drop after Phase III ovarian cancer trial
Phase III trials for Aravive’s batiraxcept in ovarian cancer and Travere’s Filspari in FSGS failed, reducing their LoA. VYNE’s VYN201 showed positive Phase Ib results in vitiligo. Moderna’s MEDI1191, Drug Farm’s DF-006, and Alexion’s ALXN-2220 completed Phase I trials, increasing their PTSR in solid tumors, hepatitis B, and ATTR-CM, respectively.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath